Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: rheuma plus 3/2020

21.01.2020 | Kollagenosen

Systemische Sklerose

Teil 2: Therapie

verfasst von: Dr. H. Findeisen, H. Grasshoff, Prof. Dr. G. Riemekasten

Erschienen in: rheuma plus | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Die systemische Sklerose ist eine seltene Autoimmunerkrankung – den Kollagenosen zugehörig. Vaskulopathie, Fibrose der Haut und Beteiligung der inneren Organe sind ausgesprochen heterogen und die Genese jener Krankheitsbilder bisher unverstanden. In den letzten Jahrzehnten sind einige Fortschritte im Management und in der Therapie erzielt worden, wobei weiterhin eher die Stabilisierung und Vermeidung von Krankheitssymptomen als die Verbesserung und Remissionserzielung erzielt werden können. In dieser Übersichtsarbeit möchten wir einen aktuellen Blick auf die wichtigen klinischen und therapeutischen Optionen werfen.
Literatur
1.
Zurück zum Zitat Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 7. Mai 2009;360(19):1989–2003. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 7. Mai 2009;360(19):1989–2003.
2.
Zurück zum Zitat Wigley FM, Flavahan NA. Raynaud’s Phenomenon. Campion EW, Herausgeber. N Engl J Med. 11. August 2016;375(6):556–65. Wigley FM, Flavahan NA. Raynaud’s Phenomenon. Campion EW, Herausgeber. N Engl J Med. 11. August 2016;375(6):556–65.
3.
Zurück zum Zitat Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349 CrossRef Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349 CrossRef
4.
Zurück zum Zitat Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E et al (2016) Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE 11(10):e163894 CrossRef Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E et al (2016) Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE 11(10):e163894 CrossRef
5.
Zurück zum Zitat Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 8. November 2005;112(19):2980–5. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 8. November 2005;112(19):2980–5.
6.
Zurück zum Zitat Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R et al (2010) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatol Oxf Engl 49(12):2420–2428 CrossRef Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R et al (2010) Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatol Oxf Engl 49(12):2420–2428 CrossRef
7.
Zurück zum Zitat Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD953 Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD953
8.
Zurück zum Zitat Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, u. a. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1. Februar 1994;120(3):199–206. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, u. a. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1. Februar 1994;120(3):199–206.
9.
Zurück zum Zitat Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19(5):503–508 PubMed Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19(5):503–508 PubMed
10.
Zurück zum Zitat Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS‑2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32–38 CrossRef Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS‑2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32–38 CrossRef
11.
Zurück zum Zitat Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, u. a. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology. 1. Juli 2010;49(7):1336–45. Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, u. a. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology. 1. Juli 2010;49(7):1336–45.
14.
Zurück zum Zitat Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339 CrossRef Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339 CrossRef
15.
Zurück zum Zitat Kuzuya K, Tsuji S, Matsushita M, Ohshima S, Saeki Y. Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat. Cureus. 26. März 2019;11(3):e4327. Kuzuya K, Tsuji S, Matsushita M, Ohshima S, Saeki Y. Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat. Cureus. 26. März 2019;11(3):e4327.
16.
Zurück zum Zitat Humbert M, Coghlan JG, Ghofrani H‑A, Grimminger F, He J‑G, Riemekasten G et al (2017) Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT‑1 and PATENT‑2. Ann Rheum Dis 76(2):422–426 CrossRef Humbert M, Coghlan JG, Ghofrani H‑A, Grimminger F, He J‑G, Riemekasten G et al (2017) Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT‑1 and PATENT‑2. Ann Rheum Dis 76(2):422–426 CrossRef
17.
Zurück zum Zitat Ngian G‑S, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, u. a. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 5. Oktober 2012;14(5):R213. Ngian G‑S, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, u. a. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 5. Oktober 2012;14(5):R213.
18.
Zurück zum Zitat Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian G‑S et al (2017) Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther 19(1:122 CrossRef Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian G‑S et al (2017) Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther 19(1:122 CrossRef
19.
Zurück zum Zitat Galiè N, Barberà JA, Frost AE, Ghofrani H‑A, Hoeper MM, McLaughlin VV, u. a. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 27. August 2015;373(9):834–44. Galiè N, Barberà JA, Frost AE, Ghofrani H‑A, Hoeper MM, McLaughlin VV, u. a. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 27. August 2015;373(9):834–44.
20.
Zurück zum Zitat Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, u. a. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 1. November 2015;192(9):1102–10. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, u. a. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 1. November 2015;192(9):1102–10.
21.
Zurück zum Zitat Willems LM, Vriezekolk JE, Schouffoer AA, Poole JL, Stamm TA, Boström C et al (2015) Effectiveness of Nonpharmacologic Interventions in Systemic Sclerosis: A Systematic Review. Arthritis Care Res 67(10):1426–1439 CrossRef Willems LM, Vriezekolk JE, Schouffoer AA, Poole JL, Stamm TA, Boström C et al (2015) Effectiveness of Nonpharmacologic Interventions in Systemic Sclerosis: A Systematic Review. Arthritis Care Res 67(10):1426–1439 CrossRef
22.
Zurück zum Zitat Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44(6):1351–1358 CrossRef Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44(6):1351–1358 CrossRef
24.
Zurück zum Zitat Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719 CrossRef Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719 CrossRef
25.
Zurück zum Zitat Moazedi-Fuerst F, Kielhauser S, Brickmann K, Hermann J, Lutfi A, Meilinger M et al (2014) Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 43(3):257–258 CrossRef Moazedi-Fuerst F, Kielhauser S, Brickmann K, Hermann J, Lutfi A, Meilinger M et al (2014) Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 43(3):257–258 CrossRef
26.
Zurück zum Zitat van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, u. a. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 25. Juni 2014;311(24):2490–8. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, u. a. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 25. Juni 2014;311(24):2490–8.
27.
Zurück zum Zitat Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 15. März 2018;378(11):1066–7. Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 15. März 2018;378(11):1066–7.
28.
Zurück zum Zitat Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S et al (2014) Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement‑a retrospective study. Rheumatol Int 34(12):1691–1699 CrossRef Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S et al (2014) Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement‑a retrospective study. Rheumatol Int 34(12):1691–1699 CrossRef
29.
Zurück zum Zitat Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, u. a. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. N Engl J Med. 27. Juni 2019;380(26):2518–28. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, u. a. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. N Engl J Med. 27. Juni 2019;380(26):2518–28.
30.
Zurück zum Zitat Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, u. a. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 1. Juli 2015;125(7):2795–807. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, u. a. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 1. Juli 2015;125(7):2795–807.
31.
Zurück zum Zitat Lee ATY, Burnet S. Corticosteroid-induced scleroderma renal crisis. Med J Aust. 21. Oktober 2002;177(8):459. Lee ATY, Burnet S. Corticosteroid-induced scleroderma renal crisis. Med J Aust. 21. Oktober 2002;177(8):459.
32.
Zurück zum Zitat Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S et al (2005) Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 64(9):1268–1273 CrossRef Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S et al (2005) Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 64(9):1268–1273 CrossRef
33.
Zurück zum Zitat Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 33(12):2464–2469 PubMed Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 33(12):2464–2469 PubMed
34.
Zurück zum Zitat Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, u. a. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis.2019 Nov;78(11):1576–1582. https://​doi.​org/​10.​1136/​annrheumdis-2019-215486 Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, u. a. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis.2019 Nov;78(11):1576–1582. https://​doi.​org/​10.​1136/​annrheumdis-2019-215486
35.
Zurück zum Zitat De Luca G, Bosello SL, Gabrielli FA, Berardi G, Parisi F, Rucco M et al (2016) Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. PLoS ONE 11(4):e153012 CrossRef De Luca G, Bosello SL, Gabrielli FA, Berardi G, Parisi F, Rucco M et al (2016) Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. PLoS ONE 11(4):e153012 CrossRef
36.
Zurück zum Zitat Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M et al (2014) Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 43(4):526–535 CrossRef Pieroni M, De Santis M, Zizzo G, Bosello S, Smaldone C, Campioni M et al (2014) Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 43(4):526–535 CrossRef
37.
Zurück zum Zitat Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE et al (2017) Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 37(1):75–84 CrossRef Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE et al (2017) Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 37(1):75–84 CrossRef
38.
Zurück zum Zitat Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol Hoboken NJ. (2018) 70(11), S 1820–1828 Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol Hoboken NJ. (2018) 70(11), S 1820–1828
39.
Zurück zum Zitat Furnari M, Savarino V, de Bortoli N, Savarino E (2016) Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmun Rev 15(12):1208–1209 CrossRef Furnari M, Savarino V, de Bortoli N, Savarino E (2016) Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmun Rev 15(12):1208–1209 CrossRef
40.
Zurück zum Zitat Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M et al (2017) Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther 19(1:145 CrossRef Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M et al (2017) Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther 19(1:145 CrossRef
41.
Zurück zum Zitat Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larché M. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology. 1. Oktober 2018;57(10):1802–11. Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larché M. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology. 1. Oktober 2018;57(10):1802–11.
43.
Zurück zum Zitat Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A (2006) Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65(6):834–835 CrossRef Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A (2006) Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 65(6):834–835 CrossRef
44.
Zurück zum Zitat Valenzuela A, Calcinosis CL (2015) pathophysiology and management. Curr Opin Rheumatol 27(6):542–548 CrossRef Valenzuela A, Calcinosis CL (2015) pathophysiology and management. Curr Opin Rheumatol 27(6):542–548 CrossRef
45.
Zurück zum Zitat Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatol Oxf Engl 40(9):1038–1043 CrossRef Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatol Oxf Engl 40(9):1038–1043 CrossRef
Metadaten
Titel
Systemische Sklerose
Teil 2: Therapie
verfasst von
Dr. H. Findeisen
H. Grasshoff
Prof. Dr. G. Riemekasten
Publikationsdatum
21.01.2020
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 3/2020
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-019-00315-4